Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

Sonvico, Fabio; Clementino, Adryana; Buttini, Francesca; Colombo, Gaia; Pescina, Silvia; Guterres, Sílvia Stanisçuaski; Pohlmann, Adriana Raffin; Nicoli, Sara

doi:10.3390/pharmaceutics10010034

Cited by 243 publications

(147 citation statements)

References 174 publications

(192 reference statements)

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…One possibility in this context is the use of nanoparticles or liposomes as vehicles, which may improve pharmacokinetic properties and bioavailability of the compounds. 39 Provided that the data obtained by studying additional parameters of Activin A and SerpinB2 application in mice faithfully reflect the situation in humans, such information may help predict therapeutic benefits in realistic clinical settings where the start of treatment after disease onset is variable.…”

Section: Therapeutic Time Window and Clinical Applicationsmentioning

confidence: 99%

Post-injury Nose-to-Brain Delivery of Activin A and SerpinB2 Reduces Brain Damage in a Mouse Stroke Model

2018

View full text Add to dashboard Cite

Synaptic NMDA receptors activating nuclear calcium-driven adaptogenomics control a potent body-own neuroprotective mechanism, referred to as acquired neuroprotection. Viral vector-mediated gene transfer in conjunction with stereotactic surgery has previously demonstrated the proficiency of several nuclear calcium-regulated genes to protect in vivo against brain damage caused by toxic extrasynaptic NMDA receptor signaling following seizures or stroke. Here we used noninvasive nose-to-brain administration of Activin A and SerpinB2, two secreted nuclear calcium-regulated neuroprotectants, for post-injury treatment of brain damage following middle cerebral artery occlusion (MCAO) in C57BL/6N mice. The observed reduction of the infarct volume was comparable to the protection obtained by intracerebroventricular injection of recombinant Activin A or SerpinB2 or by stereotactic delivery 3 weeks prior to the injury of a recombinant adeno-associated virus containing an expression cassette for the potent neuroprotective transcription factor Npas4. These results establish post-injury, nose-to-brain delivery of Activin A and SerpinB2 as effective and possibly clinically applicable treatments of acute and chronic neurodegenerative conditions.

show abstract

Section: Therapeutic Time Window and Clinical Applicationsmentioning

confidence: 99%

Post-injury Nose-to-Brain Delivery of Activin A and SerpinB2 Reduces Brain Damage in a Mouse Stroke Model

2018

View full text Add to dashboard Cite

show abstract

“…This will let particles diffuse according to their charge or/and polarity. It has been observed that by developing small nanocarriers combined with an encapsulating polymer, it is possible to increase the diffusion in the mucus (Sonvico et al, 2018). Indeed, polymers such as polyethylene glycols allow particles to avoid interactions with mucus mucins and thus to achieve a better mucopenetration.…”

Section: Evaluation Of the Mucoadhesionmentioning

confidence: 99%

“…A few reviews have addressed in detail the formulation aspect of nasal administration, with a special focus on: nanocarriers for nose-tobrain delivery (Sonvico et al, 2018), nasal powders (Tiozzo Fasiolo et al, 2018), mucoadhesive polymers (Chaturvedi et al, 2011), nasal formulation parameters (Dondeti et al, 1996), chitosan for nasal formulations (Casettari and Illum, 2014) and the nasal delivery of high molecular weight drugs (Ozsoy et al, 2009). Besides the formulation aspect, nasal delivery requires a device to aerosolize the formulation to allow its deposition in the nasal cavity.…”

Section: Introductionmentioning

confidence: 99%

How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods

Salade

Wauthoz

Goole

et al. 2019

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Nasal delivery offers many benefits over other conventional routes of delivery (e.g. oral or intravenous administration). Benefits include, among others, a fast onset of action, non-invasiveness and direct access to the central nervous system. The nasal cavity is not only limited to local application (e.g. rhinosinusitis) but can also provide direct access to other sites in the body (e.g. the central nervous system or systemic circulation). However, both the anatomy and the physiology of the nose impose their own limitations, such as a small volume for delivery or rapid mucociliary clearance. To meet nasal-specific criteria, the formulator has to complete a plethora of tests, in vitro and ex vivo, to assess the efficacy and tolerance of a new drug-delivery system. Moreover, depending on the desired therapeutic effect, the delivery of the drug should target a specific pathway that could potentially be achieved through a modified release of this drug. Therefore, this review focuses on specific techniques that should be performed when a nasal formulation is developed. The review covers both the tests recommended by regulatory agencies (e.g. the Food and Drug Administration) and other complementary experiments frequently performed in the field.

show abstract

“…Besides, NP may offer improved drug delivery to the brain since they can prevent extracellular transport by P-glycoprotein (P-gp) efflux proteins localized in the olfactory epithelium and the endothelial cells that surround the olfactory bulb [114,115]. Additionally, the nanocarriers may also have their functionalized surface with specific ligands to transport agents even more effectively through the BBB [116]. [134].…”

Section: Drug Delivery Systems For Nose-to-brain Delivery In Glioblasmentioning

confidence: 99%

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Bruinsmann¹,

Vaz²,

Alves³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most lethal form of brain tumor, characterized by rapid growth and surrounding tissue invasion. The current standard treatment is surgery followed by radiotherapy, and concurrent chemotherapy, typically with temozolomide. Although extensive research has been performed over the past years to develop an effective therapeutic strategy for the treatment of GBM, efforts have not provided major improvements in the overall survival of patients with GBM. Thus, new therapeutic approaches are urgently needed. A major challenge in the development of therapies for central nervous system (CNS) disorders is overcoming the blood–brain barrier (BBB). In this context, the intranasal (IN) route of drug administration has been proposed as a non-invasive alternative route to directly targeting the CNS. In fact, this route of drug administration may bypass the blood-brain barrier and reduce systemic side effects. Recently, formulations have been developed to further enhance nose-to-brain transport, mainly with the use of nano-sized and nanostructured drug delivery systems. The focus of this review will be on the strategies developed to deliver a number of anticancer compounds for the treatment of GBM using the nasal administration. In particular, the specific properties of nanomedicines proposed for the nose-to-brain delivery will be critically evaluated. The number of preclinical and clinical data reviewed support the idea that nasal delivery of anticancer drugs might represent a breakthrough advancement in the fight against GBM.

show abstract

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

Cited by 243 publications

References 174 publications

Post-injury Nose-to-Brain Delivery of Activin A and SerpinB2 Reduces Brain Damage in a Mouse Stroke Model

Post-injury Nose-to-Brain Delivery of Activin A and SerpinB2 Reduces Brain Damage in a Mouse Stroke Model

How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Contact Info

Product

Resources

About